THE BINDING SITE OF AMINERGIC GP ROTEIN-COUPLED RECEPTORS:
暂无分享,去创建一个
[1] K. Neve,et al. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. , 2001, Molecular pharmacology.
[2] J. Ballesteros,et al. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.
[3] D. Larhammar,et al. Site-directed mutagenesis of the 5-HT1B receptor increases the affinity of 5-HT for the agonist low-affinity conformation and reduces the intrinsic activity of 5-HT. , 2001, European journal of pharmacology.
[4] J. Saldanha,et al. The conformational switch in muscarinic acetylcholine receptors. , 2001, Life sciences.
[5] D. Sibley,et al. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. , 2001, The Journal of pharmacology and experimental therapeutics.
[6] T. Sakmar,et al. Rhodopsin: structural basis of molecular physiology. , 2001, Physiological reviews.
[7] C R Ganellin,et al. Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain , 2000, British journal of pharmacology.
[8] J. Ballesteros,et al. The Forgotten Serine , 2000, The Journal of Biological Chemistry.
[9] B. Roth,et al. Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. , 2000, Molecular pharmacology.
[10] J. Ballesteros,et al. The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.
[11] P. Pauwels,et al. Coupling of Canine Serotonin 5‐HT1B and 5‐HT1D Receptor Subtypes to the Formation of Inositol Phosphates by Dual Interactions with Endogenous Gi/o and Recombinant Gα15 Proteins , 2000, Journal of neurochemistry.
[12] K. Neve,et al. CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors. , 2000, Journal of medicinal chemistry.
[13] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[14] E. Meng,et al. Rhodopsin Sees the Light , 2000, Science.
[15] K. Page,et al. Scanning mutagenesis identifies amino acid side chains in transmembrane domain 5 of the M(1) muscarinic receptor that participate in binding the acetyl methyl group of acetylcholine. , 2000, Molecular pharmacology.
[16] B. Roth,et al. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.
[17] S. Lazareno,et al. Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor. , 2000, Molecular pharmacology.
[18] A. IJzerman,et al. TinyGRAP database: a bioinformatics tool to mine G-protein-coupled receptor mutant data. , 1999, Trends in pharmacological sciences.
[19] J. Ballesteros,et al. Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.
[20] J. Ellis,et al. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.
[21] E. Hulme,et al. Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. , 1999, Molecular pharmacology.
[22] A. IJzerman,et al. Study of Interaction between Agonists and Asn293 in Helix VI of Human β2-Adrenergic Receptor , 1999 .
[23] R. Leurs,et al. Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor* , 1999, The Journal of Biological Chemistry.
[24] H. Weinstein,et al. The Functional Microdomain in Transmembrane Helices 2 and 7 Regulates Expression, Activation, and Coupling Pathways of the Gonadotropin-releasing Hormone Receptor* , 1999, The Journal of Biological Chemistry.
[25] C. Guenet,et al. Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. , 1999, European journal of pharmacology.
[26] D. Larhammar,et al. Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT1B receptor , 1999 .
[27] M. Scheinin,et al. Chloroethylclonidine and 2-Aminoethyl Methanethiosulfonate Recognize Two Different Conformations of the Human α2A-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.
[28] J. Ballesteros,et al. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.
[29] Thomas Gudermann,et al. Structural basis of G protein-coupled receptor function , 1999, Molecular and Cellular Endocrinology.
[30] E C Hulme,et al. The Functional Topography of Transmembrane Domain 3 of the M1 Muscarinic Acetylcholine Receptor, Revealed by Scanning Mutagenesis* , 1999, The Journal of Biological Chemistry.
[31] D. Sibley,et al. Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. , 1999, Pharmacogenetics.
[32] Xi-Ping Huang,et al. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors , 1999, British journal of pharmacology.
[33] W. Vogel,et al. Double mutant cycle analysis of aspartate 69, 97, and 103 to asparagine mutants in the m2 muscarinic acetylcholine receptor. , 1999, Archives of biochemistry and biophysics.
[34] P. Pauwels,et al. Chimeric receptor analysis of the ketanserin binding site in the human 5-Hydroxytryptamine1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding. , 1998, Molecular pharmacology.
[35] D. Colquhoun,et al. Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptors , 1998, British journal of pharmacology.
[36] F. Monsma,et al. Identification of Residues in Transmembrane Regions III and VI that Contribute to the Ligand Binding Site of the Serotonin 5‐HT6 Receptor , 1998, Journal of neurochemistry.
[37] B. Roth,et al. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. , 1998, Pharmacology & therapeutics.
[38] T. Nagao,et al. Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol. , 1998, Molecular pharmacology.
[39] Glen L Alberts,et al. Contributions of cysteine 114 of the human D3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents , 1998, British journal of pharmacology.
[40] K. Konvička,et al. A proposed structure for transmembrane segment 7 of G protein-coupled receptors incorporating an asn-Pro/Asp-Pro motif. , 1998, Biophysical journal.
[41] W. Im,et al. Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras. , 1998, Molecular pharmacology.
[42] M. Grossmann,et al. G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.
[43] D. Larhammar,et al. Mutagenesis of the human 5-HT1B receptor: differences from the closely related 5-HT1A receptor and the role of residue F331 in signal transduction. , 1998, Journal of receptor and signal transduction research.
[44] P. Leff,et al. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.
[45] D. Larhammar,et al. Site-directed mutagenesis of the human 5-HT1B receptor. , 1998, European journal of pharmacology.
[46] S. Lazareno,et al. Characterization of the allosteric interactions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor. , 1998, Molecular pharmacology.
[47] Robert P. Millar,et al. Functional Microdomains in G-protein-coupled Receptors , 1998, The Journal of Biological Chemistry.
[48] H. Kase,et al. Unique binding pocket for KW-4679 in the histamine H1 receptor. , 1998, European journal of pharmacology.
[49] M. Scheinin,et al. Chloroethylclonidine binds irreversibly to exposed cysteines in the fifth membrane-spanning domain of the human alpha2A-adrenergic receptor. , 1998, Molecular pharmacology.
[50] K. Neve,et al. Constitutive activity of a chimeric D2/D1 dopamine receptor. , 1997, Molecular pharmacology.
[51] D. Sheehan,et al. Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: the significance of Tyr403 in the binding of agonists and functional coupling. , 1997, Molecular pharmacology.
[52] H Weinstein,et al. Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.
[53] D. Nelson,et al. Mutations of transmembrane IV and V serines indicate that all tryptamines do not bind to the rat 5-HT2A receptor in the same manner. , 1997, Brain research. Molecular brain research.
[54] J. Baldwin,et al. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. , 1997, Journal of molecular biology.
[55] Gebhard F. X. Schertler,et al. Arrangement of rhodopsin transmembrane α-helices , 1997, Nature.
[56] F. Monsma,et al. Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor. , 1997, Molecular pharmacology.
[57] B. Roth,et al. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. , 1997, Molecular pharmacology.
[58] G. Liapakis,et al. Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.
[59] Marvin C. Gershengorn,et al. Interactions between Conserved Residues in Transmembrane Helices 1, 2, and 7 of the Thyrotropin-releasing Hormone Receptor* , 1997, The Journal of Biological Chemistry.
[60] R. Leurs,et al. Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor. , 1997, Molecular pharmacology.
[61] T. Sakmar,et al. Functional Interaction of Transmembrane Helices 3 and 6 in Rhodopsin , 1996, The Journal of Biological Chemistry.
[62] F. Fanelli,et al. Amino acids of the α 1B‐adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes , 1996, FEBS letters.
[63] B. Kobilka,et al. Ligand stabilization of the beta 2 adrenergic receptor: effect of DTT on receptor conformation monitored by circular dichroism and fluorescence spectroscopy. , 1996, Biochemistry.
[64] P. Jeffs,et al. Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. , 1996, Biochemistry.
[65] D. Perez,et al. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. , 1996, Molecular pharmacology.
[66] H. Akil,et al. Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction. , 1996, Molecular pharmacology.
[67] S. Hoare,et al. Regulation of D2 dopamine receptors by amiloride and amiloride analogs. , 1996, Molecular pharmacology.
[68] H. Khorana,et al. Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.
[69] J. Ballesteros,et al. Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. , 1996, Biochemistry.
[70] A. IJzerman,et al. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[71] H Weinstein,et al. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. , 1996, Molecular pharmacology.
[72] H Weinstein,et al. Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor , 1996, The Journal of Biological Chemistry.
[73] J. Javitch,et al. Differentiating dopamine D2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice. , 1996, Molecular pharmacology.
[74] J. Wess,et al. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. , 1996, Molecular pharmacology.
[75] M. Maze,et al. Arrangement of Transmembrane Domains in Adrenergic Receptors , 1996, The Journal of Biological Chemistry.
[76] J. Javitch,et al. Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. , 1995, Biochemistry.
[77] H. Akil,et al. Hydrophobic Residues of the D2 Dopamine Receptor Are Important for Binding and Signal Transduction , 1995, Journal of neurochemistry.
[78] K. Catt,et al. Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[79] R. Leurs,et al. Lysine200 located in the fifth transmembrane domain of the histamine H1 receptor interacts with histamine but not with all H1 agonists. , 1995, Biochemical and biophysical research communications.
[80] J. Wess,et al. Mutational Analysis of the Relative Orientation of Transmembrane Helices I and VII in G Protein-coupled Receptors (*) , 1995, The Journal of Biological Chemistry.
[81] H Weinstein,et al. Related Contribution of Specific Helix 2 and 7 Residues to Conformational Activation of the Serotonin 5-HT2A Receptor (*) , 1995, The Journal of Biological Chemistry.
[82] T. Kenakin,et al. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.
[83] K. Page,et al. The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis. , 1995, European journal of pharmacology.
[84] Jonathan A Javitch,et al. Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method , 1995, Neuron.
[85] B. Roth,et al. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. , 1995, Molecular pharmacology.
[86] J. Rosenbusch,et al. Structural basis for sugar translocation through maltoporin channels at 3.1 A resolution , 1995, Science.
[87] L. Limbird,et al. Mutation of an aspartate residue highly conserved among G-protein-coupled receptors results in nonreciprocal disruption of alpha 2-adrenergic receptor-G-protein interactions. A negative charge at amino acid residue 79 forecasts alpha 2A-adrenergic receptor sensitivity to allosteric modulation by mon , 1994, The Journal of biological chemistry.
[88] J. Javitch,et al. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[89] K. Jacobson,et al. Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. , 1994, The Journal of biological chemistry.
[90] H Hayashi,et al. Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194. , 1994, Biochemical and biophysical research communications.
[91] J. Wess,et al. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. , 1994, The Journal of biological chemistry.
[92] A. Karlin,et al. Electrostatic potential of the acetylcholine binding sites in the nicotinic receptor probed by reactions of binding-site cysteines with charged methanethiosulfonates. , 1994, Biochemistry.
[93] R. Leurs,et al. Site-directed mutagenesis of the histamine H1-receptor reveals a selective interaction of asparagine207 with subclasses of H1-receptor agonists. , 1994, Biochemical and biophysical research communications.
[94] M. Eck,et al. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. , 1994, Molecular pharmacology.
[95] L. Naylor,et al. Structural Studies on D2 Dopamine Receptors: Mutation of a Histidine Residue Specifically Affects the Binding of a Subgroup of Substituted Benzamide Drugs , 1994, Journal of neurochemistry.
[96] L. Naylor,et al. Site-directed mutagenesis of Tyr417 in the rat D2 dopamine receptor. , 1994, Biochemical Society transactions.
[97] R. Lefkowitz,et al. A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[98] R. Graham,et al. The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. , 1994, The Journal of biological chemistry.
[99] P. Evans,et al. Agonist‐specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems. , 1994, The EMBO journal.
[100] R. Lefkowitz,et al. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. , 1994, Molecular pharmacology.
[101] D. Oprian,et al. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness , 1994, Nature.
[102] E C Hulme,et al. Acetylcholine mustard labels the binding site aspartate in muscarinic acetylcholine receptors. , 1994, The Journal of biological chemistry.
[103] K Konvicka,et al. A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. , 1994, Molecular pharmacology.
[104] R. Loncharich,et al. Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. , 1994, Molecular pharmacology.
[105] J. Kraut,et al. Long-range structural effects in a second-site revertant of a mutant dihydrofolate reductase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[106] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[107] S. Green,et al. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.
[108] B. Kobilka,et al. Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity. , 1993, Molecular pharmacology.
[109] T. Gallaher,et al. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. , 1993, Molecular pharmacology.
[110] B. Roth,et al. A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors. , 1993, Molecular pharmacology.
[111] Gebhard F. X. Schertler,et al. Projection structure of rhodopsin , 1993, Nature.
[112] P. Chanda,et al. Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. , 1993, Molecular pharmacology.
[113] R. Lefkowitz,et al. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.
[114] J. Wess,et al. Functional role of proline and tryptophan residues highly conserved among G protein‐coupled receptors studied by mutational analysis of the m3 muscarinic receptor. , 1993, The EMBO journal.
[115] E. Parker,et al. A Single Amino Acid Difference Accounts for the Pharmacological Distinctions Between the Rat and Human 5‐Hydroxytryptamine1B Receptors , 1993, Journal of neurochemistry.
[116] B. O'dowd,et al. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.
[117] H. Lester,et al. The role of conserved aspartate and serine residues in ligand binding and in function of the 5‐HT1A receptor: A site‐directed mutation study , 1992, FEBS letters.
[118] Yi-Jun Guo,et al. Molecular basis for the interaction of histamine with the histamine H2 receptor. , 1992, The Journal of biological chemistry.
[119] H. Akil,et al. Site-directed mutagenesis of the human dopamine D2 receptor. , 1992, European journal of pharmacology.
[120] N. Pollock,et al. Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. , 1992, The Journal of biological chemistry.
[121] H. Kao,et al. Site‐directed mutagenesis of a single residue changes the binding properties of the serotonin 5‐HT2 receptor from a human to a rat pharmacology , 1992, FEBS letters.
[122] K. Neve,et al. Contributions of Conserved Serine Residues to the Interactions of Ligands with Dopamine D2 Receptors , 1992, Journal of Neurochemistry.
[123] C. Fraser,et al. Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function. , 1992, The Journal of biological chemistry.
[124] B. Kobilka,et al. Identification of a single amino acid residue responsible for the binding of a class of beta-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. , 1992, Molecular pharmacology.
[125] J. Wess,et al. Site‐directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. , 1991, The EMBO journal.
[126] S. Fuchs,et al. Antipeptide antibodies localize N-(4-azido-3-[125I] iodophenethyl)spiperone binding to the carboxyl-terminal portion of the D2 dopamine receptor. , 1991, Molecular pharmacology.
[127] B. Kobilka,et al. A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists. , 1991, The Journal of biological chemistry.
[128] K. Neve,et al. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. , 1991, Molecular pharmacology.
[129] K. Neve,et al. Regulation of dopamine D2 receptors by sodium and pH. , 1991, Molecular pharmacology.
[130] C. Strader,et al. Allele-specific activation of genetically engineered receptors. , 1991, The Journal of biological chemistry.
[131] C. A. Guyer,et al. An aspartate conserved among G-protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium. , 1990, The Journal of biological chemistry.
[132] E. Hulme,et al. Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. , 1990, The Journal of biological chemistry.
[133] C. Strader,et al. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.
[134] M. Caron,et al. Localization of the fourth membrane spanning domain as a ligand binding site in the human platelet alpha 2-adrenergic receptor. , 1989, Biochemistry.
[135] C. Strader,et al. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.
[136] C. Slaughter,et al. The catecholamine binding site of the beta-adrenergic receptor is formed by juxtaposed membrane-spanning domains. , 1988, The Journal of biological chemistry.
[137] M. Caron,et al. Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. , 1988, Science.
[138] C. Strader,et al. Identification and sequence of a binding site peptide of the beta 2-adrenergic receptor. , 1988, Biochemistry.
[139] C. Strader,et al. Identification of residues required for ligand binding to the beta-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[140] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[141] Harel Weinstein,et al. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. , 2002, Methods in enzymology.
[142] D. Sibley,et al. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. , 2000, Molecular pharmacology.
[143] H. Kikkawa,et al. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. , 1998, Molecular pharmacology.
[144] D. Perez,et al. Molecular mechanisms of ligand binding and activation in alpha 1-adrenergic receptors. , 1998, Advances in pharmacology.
[145] M. P. Turpin,et al. Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. , 1998, Journal of receptor and signal transduction research.
[146] A. Karlin,et al. Substituted-cysteine accessibility method. , 1998, Methods in enzymology.
[147] R. Glennon,et al. The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine. , 1996, Molecular pharmacology.
[148] J. Hénichart,et al. Pharmacological and functional characterisation of the wild-type and site-directed mutants of the human H1 histamine receptor stably expressed in CHO cells. , 1995, Journal of receptor and signal transduction research.
[149] S. Lazareno,et al. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. , 1995, Molecular pharmacology.
[150] C. Strader,et al. Structure-function analysis of the beta-adrenergic receptor. , 1988, Cold Spring Harbor symposia on quantitative biology.